Literature DB >> 29946875

[Pathophysiology and treatment of IgA nephropathy].

R Bollin1, H Haller2.   

Abstract

The IgA nephropathy is the most frequent form of glomerulonephritis worldwide. In approximately 30% of patients a reduction in the glomerular filtration rate of approximately 50% is observed within 10 years. Patients with IgA nephropathy form IgG autoantibodies against galactose-deficient IgA1 antibodies. This results in deposition of these antibodies in the mesangium and activation of complement with mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis and atrophying interstitial fibrosis. The basic treatment for patients with IgA nephropathy consists of removing risk factors, in particular hypertension, with blockade of the renin-angiotensin-aldosterone system. Immunosuppressives were also investigated in various studies but a clear advantage was not observed.

Entities:  

Keywords:  Autoimmune diseases; Glomerulonephritis; Hypertension; Immunosuppression; Renin-angiotensin system

Mesh:

Substances:

Year:  2018        PMID: 29946875     DOI: 10.1007/s00108-018-0443-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  38 in total

Review 1.  Corticosteroid therapy in IgA nephropathy.

Authors:  Jicheng Lv; Damin Xu; Vlado Perkovic; Xinxin Ma; David W Johnson; Mark Woodward; Adeera Levin; Hong Zhang; Haiyan Wang
Journal:  J Am Soc Nephrol       Date:  2012-04-26       Impact factor: 10.121

2.  The MEST score provides earlier risk prediction in lgA nephropathy.

Authors:  Sean J Barbour; Gabriela Espino-Hernandez; Heather N Reich; Rosanna Coppo; Ian S D Roberts; John Feehally; Andrew M Herzenberg; Daniel C Cattran
Journal:  Kidney Int       Date:  2016-01       Impact factor: 10.612

3.  Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy.

Authors:  Zhi Qiang Huang; Milan Raska; Tyler J Stewart; Colin Reily; R Glenn King; David K Crossman; Michael R Crowley; Audra Hargett; Zhixin Zhang; Hitoshi Suzuki; Stacy Hall; Robert J Wyatt; Bruce A Julian; Matthew B Renfrow; Ali G Gharavi; Jan Novak
Journal:  J Am Soc Nephrol       Date:  2016-03-10       Impact factor: 10.121

4.  Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.

Authors:  Ronald J Hogg; R Curtis Bay; J Charles Jennette; Richard Sibley; Sumit Kumar; Fernando C Fervenza; Gerald Appel; Daniel Cattran; Danny Fischer; R Morrison Hurley; Jorge Cerda; Brad Carter; Beverly Jung; German Hernandez; Debbie Gipson; Robert J Wyatt
Journal:  Am J Kidney Dis       Date:  2015-07-21       Impact factor: 8.860

5.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

Authors:  Ian S D Roberts; H Terence Cook; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Daniel C Cattran; Rosanna Coppo; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

6.  Clinical course and prognostic factors of clinical early IgA nephropathy.

Authors:  P Shen; L He; D Huang
Journal:  Neth J Med       Date:  2008-06       Impact factor: 1.422

Review 7.  Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis.

Authors:  Gaosi Xu; Weiping Tu; Dongfeng Jiang; Chengyun Xu
Journal:  Am J Nephrol       Date:  2008-10-31       Impact factor: 3.754

8.  Long-term study of mycophenolate mofetil treatment in IgA nephropathy.

Authors:  Sydney C W Tang; Anthony W C Tang; Sunny S H Wong; Joseph C K Leung; Yiu Wing Ho; Kar Neng Lai
Journal:  Kidney Int       Date:  2009-12-23       Impact factor: 10.612

Review 9.  New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.

Authors:  Riccardo Magistroni; Vivette D D'Agati; Gerald B Appel; Krzysztof Kiryluk
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

Review 10.  The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.

Authors:  Barbora Knoppova; Colin Reily; Nicolas Maillard; Dana V Rizk; Zina Moldoveanu; Jiri Mestecky; Milan Raska; Matthew B Renfrow; Bruce A Julian; Jan Novak
Journal:  Front Immunol       Date:  2016-04-12       Impact factor: 7.561

View more
  2 in total

1.  Multimodal imaging of bilateral ischemic retinal vasculopathy associated with Berger's IgA nephropathy: case report.

Authors:  Khaled El Matri; Francesca Amoroso; Olivia Zambrowski; Alexandra Miere; Eric H Souied
Journal:  BMC Ophthalmol       Date:  2021-05-08       Impact factor: 2.209

2.  Meta-Analysis of the Effectiveness and Safety of Glucocorticoid for the Treatment of IgA Kidney Disease.

Authors:  Jieqiong Sun
Journal:  J Healthc Eng       Date:  2022-03-07       Impact factor: 2.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.